Neonatal sepsis: a challenge in hemostaseology.
Several therapeutic approaches to sepsis and disseminated intravascular coagulation (DIC) have shown promising results in animal models. Large controlled trials in humans, however, have failed to show a clearly beneficial effect of a single drug or substance on outcome and survival so that treatment remains uncertain. As one researcher stated: ". . . sepsis is a classical example of a disease greater than the sum of its parts; it is a complex process in which intervention in one area might have only a modest effect on the final outcome." We believe that the complex pathophysiological setting of septic shock will undoubtedly require a multifaceted approach. Consequently, we attempt to arrest DIC and restore adequate tissue perfusion by intervention with heparin, AT and if possible protein C (PC) in the earliest stage of the disease, with the aim of blocking ongoing microthrombus formation and to support fibrinolysis. Growing understanding of the basic underlying mechanisms teaches us how to successfully stabilise the individual decompensated sub-systems like coagulation in septic patients. We should learn to accept these steps to reach the goal of a better outcome in terms of survival in this devastating illness.
Kreuz
W
W
Johann Wolfgang Goethe University Hospital, Department of Paediatrics, Frankfurt/Main, Germany.
Veldmann
A
A
Fischer
D
D
Schlösser
R
R
Volk
W R
WR
Ettingshausen
C E
CE
D000818:Animals; D000991:Antithrombins / Q000627:therapeutic use; D004211:Disseminated Intravascular Coagulation / Q000188:drug therapy / Q000503:physiopathology; D006487:Hemostasis; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000188:drug therapy; D007235:Infant, Premature, Diseases / Q000188:drug therapy; D018805:Sepsis / Q000188:drug therapy
D000991:Antithrombins; D006493:Heparin